PeptideLabs Logo
PeptideLabs
All profiles

Cotadutide

Peptide · Metabolism & GLP-1

Has been studied clinically for glucose control, body weight, and liver and kidney markers.

In clinical researchWADA
LibraryNo account · this device only

Also known as: MEDI0382 · GLP-1/glucagon

Use at a glance

Cotadutide

Has been studied clinically for glucose control, body weight, and liver and kidney markers.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Study information · not a personal use plan

Product or source: Cotadutide · NCT04515849

What amount?
100 µg
How often?
once per day · 26 weeks
What time of day?
Time of day not stated here; see the study plan
In what setting?
Separate study group (phase 2)
How is it used?
Studies or online reports describe particular uses. They do not establish a general instruction for vendor products.
Does it need mixing?
No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.
View preparationCheck sources
Overview of all entries

  • Cotadutide · Separate study group (phase 2)

    Study information · not a personal use plan · NCT04515849

    100 µg · once per day · 26 weeks · Time of day not stated here; see the study plan

  • Cotadutide · Separate study group (phase 2)

    Study information · not a personal use plan · NCT04515849

    300 µg · once per day · 26 weeks · Time of day not stated here; see the study plan

  • Cotadutide · Separate study group (phase 2)

    Study information · not a personal use plan · NCT04515849

    600 µg · once per day · 26 weeks · Time of day not stated here; see the study plan

More factsPeptide · Metabolism & GLP-1
Classification
Peptide · Metabolism & GLP-1
Research focus
Has been studied clinically for glucose control, body weight, and liver and kidney markers.
Evidence
In clinical trials
Status
In clinical research

Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.

Schedule explained in detailClinical research

Amount status

Study arms only: NCT04515849 investigated 100, 300 and 600 µg daily over 26 weeks. Not an approved or personal dose.

Profile evidence level: clinical.

Timing

Daily, strictly within the controlled study protocol.

No individual recommendation.

Cycle/duration

26 weeks was the study duration, not a community cycle; a current approval basis is lacking.

No individual recommendation.

Mixing & calculations

No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.

All preparation informationProduct details and calculation examples from the available sources.

No documented community reconstitution, U-100 table or authorised storage. Study formulations do not transfer to unknown vials.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Glucagon and GLP-1 receptor agonist

Cotadutide is classified as “Glucagon and GLP-1 receptor agonist”. Has been studied clinically for glucose control, body weight, and liver and kidney markers. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Glucagon/GLP-1 combined action

Researchers test whether combining glucagon and GLP-1 signalling increases energy expenditure in addition to appetite suppression. Liver fat levels and weight trajectory are compared against pure GLP-1 agents.

02

Body weight and metabolism

Researchers track changes in body weight, body composition, and metabolic markers such as blood sugar or cholesterol over the course of a study. This is similar to following someone's weight and lab values over months to see broader trends rather than day-to-day fluctuations.

03

Liver and cardiorenal outcomes

This looks at effects on liver fat, heart function, and kidney markers, organs that are closely linked through shared metabolic and blood flow pathways. Studies typically measure liver fat imaging, blood pressure, and kidney function tests over time.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Weight management forums

In these forums, users compare their own weight trajectories, side effects, and perceived appetite changes between different products. Before-and-after photos and personal timelines are often shared. Such anecdotes and vendor marketing claims are not scientific proof of efficacy.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Stack and blend discussion

Users exchange self-assembled combinations of several peptides and compare perceived effects, often without the specific combination ever having been studied. Such stack recommendations are personal opinions, not vetted protocols.

Adverse effects and safety risks

  • Gastrointestinal effects, dehydration, and changes in glucose or appetite may occur depending on the target; incretin medicines can also carry gallbladder, pancreatic and retinopathy warnings.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Pregnancy, severe gastric-emptying disorders, and relevant pancreatic, gallbladder, renal or endocrine disease require professional assessment; the exact label may add contraindications.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Depending on substance and indication, weight, blood pressure, hydration, glucose/HbA1c, kidney and liver markers, and concomitant medicines may be reviewed; symptoms guide further tests.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

In clinical trials

Clinical studies exist, but general approval does not.

Clinical evidence

The substance is currently being studied in structured human clinical trials, but a general approval does not yet exist.

Cotadutide has also been studied for liver and kidney markers, unlike GLP-1 agonists focused purely on glucose and weight.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

In clinical research

A clinical-development candidate, not an approved medicinal product.

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile